Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis AG : The calm spell can be taken advantage of to put on new positions

05/26/2020 | 02:33am EST
long trade
Stop-loss triggered
Entry price : 83.68CHF | Target : 88CHF | Stop-loss : 80.5CHF | Potential : 5.16%
The price of Novartis AG shares is range-bound. This phase will end sooner or later when volatility comes back.
Investors have an opportunity to buy the stock and target the CHF 88.
Novartis AG : Novartis AG : The calm spell can be taken advantage of to put on new positions
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

  • The group usually releases earnings worse than estimated.
  • The company's enterprise value to sales, at 3.97 times its current sales, is high.

© MarketScreener.com 2020
Stocks mentioned in the article
ChangeLast1st jan.
AT HOME GROUP INC. 0.56% 25.07 Delayed Quote.62.16%
NOVARTIS AG -2.96% 83.7 Delayed Quote.2.96%

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 49 122 M - -
Net income 2020 8 379 M - -
Net Debt 2020 20 219 M - -
P/E ratio 2020 26,4x
Yield 2020 3,28%
Capitalization 221 B 220 B -
EV / Sales 2020 4,90x
EV / Sales 2021 4,49x
Nbr of Employees 110 000
Free-Float 86,4%
Upcoming event on NOVARTIS AG
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 110,11 $
Last Close Price 96,97 $
Spread / Highest target 53,6%
Spread / Average Target 13,6%
Spread / Lowest Target -6,93%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.96%220 401
JOHNSON & JOHNSON5.46%436 949
ROCHE HOLDING AG3.82%309 894
PFIZER INC.1.28%207 217
MERCK & CO., INC.-0.79%205 312
ABBVIE INC.3.13%195 085